Multifamily Real Estate in Philadelphia, PA

Cap rates for multifamily properties in Philadelphia vary by submarket, property class, and occupancy levels. The overall Philadelphia market average cap rate is approximately 6.5%. Class A properties typically trade at lower cap rates than value-add opportunities.

Cap rates for multifamily vary significantly by market, class, and vintage. Class A properties in gateway markets may trade at 4.0-5.0%, while Class B and C assets in secondary markets typically range from 5.5-7.5%. Value-add deals with below-market rents may show going-in cap rates of 4.5-5.5% with projected stabilized cap rates of 6.0-7.0% after renovations.

Key evaluation metrics include price per unit relative to replacement cost, in-place and market rent comparisons, occupancy trends, operating expense ratios, and trailing and pro forma NOI. Investors also analyze the rent roll for lease expiration concentration, unit mix, loss-to-lease, and concession levels. Location fundamentals like job growth, population trends, and supply pipeline are equally important.

Philadelphia offers 100-200 basis points higher cap rates than comparable New York assets, providing a meaningful yield premium. The metro benefits from proximity to New York (90 minutes by train) while maintaining its own deep employment base. Life sciences, healthcare, and education institutions provide recession-resistant demand that New York's more finance-dependent economy does not always match. However, Philadelphia's total market liquidity and appreciation potential are more modest than New York.

The University of Pennsylvania, Drexel, Temple, and Jefferson health systems generate enormous research funding that spins off into commercial lab and office demand. University City's uCity Square and Schuylkill Yards developments are adding millions of square feet of purpose-built lab space. The metro is the second-largest cell and gene therapy hub in the US after the Boston-Cambridge corridor. Major pharma companies including GSK, Merck, and AstraZeneca maintain significant operations in the region.